Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device
This article was originally published in The Gray Sheet
Executive Summary
Sorin’s $20 million investment will help Respicardia continue the U.S. pivotal trial of the remedē implantable phrenic nerve stimulator for sleep apnea and give Sorin exclusive rights to distribute the device in select European countries, where it has a CE mark but has yet to be launched.